Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;54(9):2479-2481.
doi: 10.1016/j.transproceed.2022.09.001. Epub 2022 Sep 23.

Immunity After Vaccination Against SARS-CoV-2 in Lung Transplant?

Gema María Siesto López  1 , Rodrigo Alonso Moralejo  2 , María Piñeiro Roncal  3 , María Teresa Tejedor Ortiz  2 , Carlos Andrés Quezada Loaiza  2 , Alfredo Pérez Rivilla  4 , Alicia De Pablo Gafas  2
Affiliations

Immunity After Vaccination Against SARS-CoV-2 in Lung Transplant?

Gema María Siesto López et al. Transplant Proc. 2022 Nov.

Abstract

Background: SARS-CoV2 infection causes high morbidity and mortality in lung transplant (LT) recipients. Vaccination with messenger RNA vaccines has been shown to play a key role in controlling the severity of infection in the general population. The aim of our study is to analyze whether vaccination with 2 doses of SARS-Cov2 provides immunity in LT recipients.

Methods: Retrospective descriptive and analytical study of LT recipients vaccinated with 2 doses of SARS-CoV2. We analyzed the vaccine received, if they had COVID-19, antibody levels (antispike and antinucleoprotein), anticalcineurin levels, infections in the last year, and presence of neoplasias.

Results: The most commonly administered vaccine was from Moderna, with 27% of patients showing immunity with a median antibody levels of 4.81 binding antibody units/mL, far from the values considered protective (> 34 binding antibody units/mL). Thirteen patients were infected with SARS-CoV2, 7 post vaccination (5 of them were antispike-positive). No relationship was demonstrated between generation of immunity and age and level of immunosuppression.

Conclusions: Vaccination against SARS-CoV2 in LT recipients generates limited and ineffective immunity with only 2 doses.

PubMed Disclaimer

References

    1. Scharringa S, Hoffman T, van Kessel DA, et al. Vaccination and their importance for lung transplant recipients in a COVID-19 world. Expert Rev Clin Pharmacol. 2021;14:1413–1425. - PubMed
    1. Mohammed AH, Blebil A, Dujaili J, et al. The risk and impact of COVID-19 pandemic on immunosuppressed patients: cancer, HIV, and solid organ transplant recipients. AIDS Rev. 2020;22:151–157. - PubMed
    1. Messika J, Eloy P, Roux A, et al. COVID-19 in lung transplant recipients. Transplantation. 2021;105:177–186. - PubMed
    1. Umakanthan S, Sahu P, Ranade AV, et al. Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19) Postgrad Med J. 2020;96:753–758. - PMC - PubMed
    1. Havlin J, Svorcova M, Dvorackova E, et al. Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients. J Heart Lung Transplant. 2021;40:754–758. - PMC - PubMed